Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2026 · 10-Q
Revenue$41.00K$41.00K−62.4% vs Q1 2025 Net Income-$12.35M-$12.35MN/M vs Q1 2025 EPS Diluted-$0.18-$0.18N/M vs Q1 2025 Operating Income-$12,850,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Margins · derivedOperating margin-31341.5%−18147.0 pt vs Q1 2025
Net margin-30109.8%−17785.0 pt vs Q1 2025
ended Mar 31, 2026 · filed May 14, 2026 · 44 d after period end